Dr. Kavita Kalidas, MD

Dr. Kalidas practices at Neuroscience Consultants in Medley, Florida.

Dr. Kalidas' NPI, 1831388867, was assigned on October 16, 2007. Dr. Kalidas graduated from Ross University School of Medicine in 2005. Dr. Kalidas holds Florida license ME101778.

Dr. Kalidas' primary practice is Neuroscience Consultants, at 9960 Nw 116th Way, Medley, FL 33178 in Miami-Dade County. The practice phone is (786) 924-1311.

Dr. Kalidas' primary practice is Neuroscience Consultants in Medley, Florida. Dr. Kalidas is also affiliated with BayCare St. Joseph's Hospital. The medical group on file is First Choice Neurology. Dmand AI also links Dr. Kalidas to 1 more hospital, 1 group practice or clinic and 1 home health agency, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Kalidas practices, 4 sites in all. Vendor and product names are available with a free account.

Neurology is Dr. Kalidas' primary specialty in the NPI Registry, under taxonomy code 2084N0400X. Dr. Kalidas is board certified in neurology by the American Board of Psychiatry and Neurology. Dr. Kalidas is licensed in Florida.

Dmand AI lists fibromyalgia and chronic pain, hypersomnia, lower back pain and migraine and chronic headache among the conditions Dr. Kalidas treats.

CMS data shows 29 Medicare services from Dr. Kalidas across 2 procedure codes in 2024, all of them office visits, for 29 Medicare patients. Medicare paid $4,027 for them. Every service was in an office.

CMS counts 29 Medicare patients who saw Dr. Kalidas in 2024. The largest group is 65 to 74, with 18 patients. 75% of them have high cholesterol, and 66% have high blood pressure. Their average risk score is 0.85, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Dr. Kalidas' median patient age at 51, with 74% women.

In 2024, Dr. Kalidas wrote 415 Medicare Part D claims for 123 patients. 82% of them were for generic drugs. CMS names the drug for 204 of them, across 11 drugs with 11 or more claims each, at $61,107 in total drug cost. In 2023, CMS named 1,532 claims across 36 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 0 out of 100 for Dr. Kalidas for performance year 2024, reported as part of a group. Dr. Kalidas accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Kalidas as offering telehealth.

Dmand AI links 9 papers to Dr. Kalidas, published from 2013 to 2020. 2020 was the busiest year, with 3. The most frequent topics are Migraine Disorders, Antibodies, Monoclonal, Humanized and Double-Blind Method. Dr. Kalidas has published most often in Headache. Dr. Kalidas' most frequent co-authors are David W. Dodick, MD, Eric Peter Baron, DO and Eric Michael Pearlman, MD, PhD.

Dmand AI links Dr. Kalidas to 11 clinical trials. 4 are still active or recruiting. Conditions studied include Migraine Disorders, Headache Disorders, Primary and Cluster Headache. Eli Lilly and Company sponsors the most, 10. Open Payments lists research payments to Dr. Kalidas that name 10 trials.

CMS Open Payments shows 1,612 general payments to Dr. Kalidas from 35 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 76% of the total. Abbvie Inc. paid the most, $466,397. It also lists 26 research payments totaling $55,901 from 2016 to 2022, naming 10 clinical trials.

Dr. Kalidas graduated from Ross University School of Medicine in 2005.

Dr. Kalidas is in network with 7 carriers, including Aetna, Cigna and United Healthcare. Medicare plans come from the most carriers, 5. Check the plan with the practice before a visit.